Phase II evaluation of treatment of complete resection of hepatic metastases from colorectal cancer and adjuvant hepatic arterial infusion of floxuridine: an Eastern Cooperative Oncology Group Study (PB083).

Berlin J, Merrick HW, Smith TJ, Lerner H
Am J Clin Oncol. 1999 22 (3): 291-3

PMID: 10362339 · DOI:10.1097/00000421-199906000-00016

This study was designed to evaluate hepatic arterial infusion of floxuridine (FUDR) in patients with resected hepatic metastases from colorectal cancer. Patients who met eligibility criteria had an Infusaid pump (Infusaid Corporation, Sharon, MA, U.S.A.) implanted for intraarterial administration of chemotherapy. After complete surgical resection of hepatic metastases, FUDR (0.2 mg/kg/day) was given in 28-day cycles consisting of 14 days of treatment followed by 14 days of rest. Of 11 patients enrolled, one was ineligible, one received no treatment because of a blocked pump, and nine were treated per protocol. Of the nine treated patients, all are dead: one from hepatic toxicity, one from unrelated causes, and seven from progressive disease. Grade 3-4 toxicity included three cases of gastritis and two cases of hepatotoxicity from FUDR. Although this regimen was not successful, in part because of toxicity, the patient population studied here should be considered for future studies of adjuvant therapy.

MeSH Terms (15)

Adult Aged Antimetabolites, Antineoplastic Chemotherapy, Adjuvant Colorectal Neoplasms Female Floxuridine Hepatectomy Hepatic Artery Humans Infusions, Intra-Arterial Liver Neoplasms Male Middle Aged Pilot Projects

Connections (1)

This publication is referenced by other Labnodes entities: